Teva is evidently not planning to launch until the appellate court rules on the validity of LLY’s 5,464,826 “use” patent, which is scheduled for a hearing on 5/7/10. Inasmuch as this patent has already been declared unenforceable by the lower court, it’s somewhat surprising that Teva is not launching immediately.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.